Insulet Co. (NASDAQ:PODD) Shares Bought by APG Asset Management N.V.

APG Asset Management N.V. increased its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 687.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 41,462 shares of the medical instruments supplier's stock after purchasing an additional 36,199 shares during the quarter. APG Asset Management N.V. owned approximately 0.06% of Insulet worth $10,453,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of PODD. Norges Bank bought a new stake in Insulet during the 4th quarter worth about $248,806,000. Raymond James Financial Inc. purchased a new stake in shares of Insulet in the 4th quarter valued at about $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in Insulet in the 4th quarter worth $53,184,000. Artisan Partners Limited Partnership boosted its position in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after purchasing an additional 149,524 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Insulet in the fourth quarter valued at $28,422,000.

Insulet Stock Down 2.2 %

PODD traded down $5.67 on Wednesday, hitting $250.75. The company had a trading volume of 171,243 shares, compared to its average volume of 715,151. The firm has a market capitalization of $17.61 billion, a P/E ratio of 43.31, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a fifty day simple moving average of $265.46 and a 200-day simple moving average of $260.69. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on PODD shares. Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Raymond James reiterated an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and a consensus target price of $292.06.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.